Author: Ravi Shankar

Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli^™ Growth and the Commercial Launch of REZENOPY^™

Two FDA-Approved Commercial Products Position Company for Continued Sequential Revenue Growth

High Gross Margins and Established Commercial Infrastructure Provide Operating Leverage Potential as Company Targets Profitability in 2027

COMMACK, NY, Oct. 22, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today issued the following letter to shareholders.

Key Commercial and Financial Achievements During the First Nine Months of 2026

• 256% Sequential Revenue Growth: Reported preliminary, unaudited third-quarter 2026 revenue of approximately $1.22 million, compared to $343,639 in the second quarter, reflecting accelerating commercial momentum following the launch of the Scienture’s second commercial product.
• Successful Launch of Second FDA-Approved Product: Commercially launched REZENOPY^™ in August 2026, with initial wholesale shipments contributing to third-quarter revenue and establishing a second commercial revenue stream.
• 74% Sequential Increase in Arbli^™ Wholesale Unit Sales: Continued to drive commercial adoption and increasing wholesale demand for Arbli^™ during the third quarter of 2026.
• Expanded Institutional Adoption: Secured formulary additions for Arbli^™ at more than ten (10) leading U.S. pediatric academic medical centers, strengthening the product’s presence within important healthcare institutions.
• Expanded REZENOPY^™ Distribution: Advanced commercialization through a strategic distribution partnership focused on addiction treatment centers, broadening the product’s potential market reach.
• High Gross Margin Profile: Reported gross margins of approximately 97.7% in the second quarter of 2026, supporting the potential for meaningful operating leverage as revenue increases.
• Broad Commercial Market Access: REZENOPY^™ GPO agreements provide access to more than 5,000 healthcare facilities, with commercial payer and government access potentially reaching over 100 million covered lives, while Arbli^™ continues to expand its formulary placements and payer coverage, supporting broader adoption of both products.
• Strengthened Intellectual Property Portfolio: Secured U.S. patent protection for REZENOPY^™ extending into 2041, complementing Arbli^™ patent protection until 2041.

Dear Fellow Shareholders,

The first nine months of 2026 have marked a transformational period for Scienture as we transitioned into a multi-product commercial pharmaceutical company, accelerated revenue growth, and expanded the market presence of our two FDA-approved products. We believe these achievements have established a strong foundation for the next phase of our growth and represent meaningful progress toward our objective of achieving profitability in 2027.

Our preliminary, unaudited third-quarter 2026 revenue reached approximately $1.22 million, representing a 256% sequential increase over the second quarter. This performance was supported by continued commercial growth in Arbli^™, including a 74% sequential increase in wholesale unit sales, alongside initial wholesale shipments of REZENOPY^™ following its August 2026 commercial launch.

Importantly, we believe this momentum is only beginning to reflect the commercial potential of our expanding product portfolio. We believe the continued commercial traction of Arbli^™, combined with the early-stage commercialization of REZENOPY^™, positions us well to deliver continued sequential revenue growth as both products scale.

Over the past several quarters, we have invested in establishing the commercial infrastructure necessary to support our products, including sales resources, wholesale distribution, institutional market access, and payer relationships. As revenue increases, we believe this existing infrastructure, combined with our historically high gross margins, provides an opportunity to meaningfully improve operating performance without a proportionate increase in expenses.

Building Momentum Across Two FDA-Approved Commercial Products

Arbli^™ Continues to Expand Its Commercial Footprint

Arbli^™ (losartan potassium) Oral Suspension is the first and only FDA-approved, ready-to-use oral liquid formulation of losartan, addressing an established U.S. market representing approximately $218 million in annual sales and more than 73 million prescriptions, according to August 2026 IQVIA data.

This mature market has long been dominated by oral solid (tablet) formulations from generic manufacturers, with the original branded product (Cozaar) now largely genericized. The vast majority of prescriptions are tablets, leaving a meaningful underserved segment of patients, particularly elderly individuals, pediatric patients age six and older, and others with dysphagia or difficulty swallowing, who previously relied on inconsistent pharmacy compounding.

Arbli^™ addresses this unmet need through a standardized, FDA-approved oral liquid formulation that eliminates the variability associated with pharmacy compounding while offering flexible dosing, convenient room-temperature storage, and an approved 24-month shelf life. We believe these attributes provide meaningful advantages for physicians, patients, and healthcare institutions seeking consistent and convenient treatment options.

During the third quarter of 2026, Arbli^™ wholesale unit sales increased 74% sequentially, reflecting continued progress in expanding commercial demand. We have also secured the addition of Arbli^™ to the formularies of more than ten (10) leading U.S. pediatric academic medical centers, an important milestone in establishing the product within key institutional treatment settings.

We believe these developments provide a foundation for continued market share gains as we pursue additional formulary placements, broaden physician awareness, and expand patient access. Arbli^™ also benefits from U.S. patent protection extending into 2041, supporting its long-term commercial potential.

REZENOPY^™ Establishes a Second Revenue Growth Opportunity

The commercial launch of REZENOPY^™ (naloxone hydrochloride) Nasal Spray 10 mg in August 2026 represented another important milestone in Scienture’s evolution into a multi-product commercial pharmaceutical company.

According to IQVIA data (August 2026), the U.S. naloxone nasal spray market represents approximately $137 million in annual sales, with approximately 9 million units sold annually, has historically been led by lower-dose products, including Narcan® 4 mg, alongside other approved formulations and generic alternatives. The ongoing opioid crisis, particularly the prevalence of potent synthetic opioids such as fentanyl, continues to underscore the importance of access to opioid overdose reversal treatments.

REZENOPY^™ is the highest-dose FDA-approved naloxone nasal spray available in the United States, delivering 10 mg of naloxone in a single-use device for the emergency treatment of known or suspected opioid overdose. The product combines the established naloxone molecule and familiar nasal spray delivery method with a differentiated higher-dose formulation, providing an additional treatment option for healthcare providers and emergency responders.

Through our collaboration with Summit Biosciences, a subsidiary of Kindeva Drug Delivery, Scienture holds exclusive U.S. commercialization rights to REZENOPY^™, supporting our strategy to establish a differentiated presence in the naloxone market.

Initial wholesale shipments contributed to our third-quarter revenue growth, and we are focused on expanding distribution and adoption through our strategic commercialization relationships, including channels serving addiction treatment centers and healthcare institutions.

As REZENOPY^™ progresses beyond its initial launch phase, we believe increasing market access and product adoption can support continued revenue growth alongside Arbli^™. REZENOPY^™ also benefits from U.S. patent protection extending into 2041, supporting its long-term commercial potential.

High Gross Margins and Operating Leverage Support Our Path Toward Profitability

Beyond our commercial achievements, we view one of the most compelling aspects of Scienture’s business model as the potential for significant operating leverage as revenue scales.

We believe we have made meaningful progress in improving our financial performance and operating cost structure. During the second quarter of 2026, operating expenses decreased approximately 41% to $3.0 million, compared to $5.2 million in the prior-year period. Our operating loss improved approximately 48% to $2.7 million, compared to $5.2 million in the second quarter of 2025, while net loss narrowed approximately 58% to $2.8 million, compared to $6.7 million in the prior-year period.

Importantly, we reported gross margins of approximately 97.7% during the second quarter of 2026, demonstrating the attractive economics of our commercial product portfolio. We believe these historically high gross margins, combined with continued revenue growth and disciplined expense management, provide an opportunity to further reduce operating losses as sales scale.

We have already established much of the commercial infrastructure required to support both products, including national sales resources, wholesale distribution relationships, and institutional market access. As sales volumes increase, we believe we can leverage these existing capabilities without a proportionate increase in operating expenses.

Our focus remains on maximizing the revenue potential of the commercial platform we have built while maintaining financial discipline. We believe the combination of accelerating revenue growth, high gross margins, and an improved operating cost structure positions Scienture to make meaningful progress toward our objective of achieving profitability in 2027.

Expanding Market Access and Strengthening Our Commercial Platform

A key component of our strategy has been establishing the distribution and market access capabilities necessary to support sustained commercial growth of both Arbli^™ and REZENOPY^™.

For REZENOPY^™, group purchasing organization (“GPO”) agreements provide access to more than 5,000 healthcare facilities, while commercial payer coverage and government access through CMS have the potential to reach more than 100 million covered lives.

Arbli^™ also continues to gain commercial traction, with wholesale unit sales increasing 74% sequentially in the third quarter. We secured additional formulary placements, expanded commercial access, and built on prior GPO and payer coverage wins, including expansions reaching approximately 12.5 million additional covered lives.

Together, these developments, supported by our national sales resources and wholesale distribution capabilities, strengthen our commercial platform. We believe this infrastructure will enable us to scale revenue more efficiently, improve operating leverage, and support our goal of achieving profitability in 2027.

Competitive Advantages Position Scienture for Continued Market Share Gains

We believe Scienture is well positioned to capture market share in established pharmaceutical markets through a combination of differentiated FDA-approved products, long-term intellectual property protection, and an established commercial infrastructure.

Our competitive advantage is built on three key strengths: differentiated 505(b)(2)-style formulations that address unmet patient needs within large, established markets; U.S. patent protection extending into 2041 for Arbli^™ and REZENOPY^™; and a focused commercial platform encompassing national sales resources, GPO and payer relationships, wholesale distribution, institutional formulary access, and patient support capabilities.

Our strategy for increasing market share centers on expanding institutional and hospital formulary adoption, broadening payer coverage, strengthening physician engagement, and increasing product utilization across retail and institutional channels. We believe these initiatives will help drive continued sequential sales growth while leveraging our existing commercial infrastructure.

Importantly, both products address established markets with meaningful opportunities for penetration. Even modest market share gains within the approximately $218 million U.S. losartan market, combined with increasing adoption in the approximately $137million naloxone nasal spray market, could translate into meaningful incremental revenue. Given our historically high gross margins, we believe these opportunities can contribute significantly to improving operating performance as sales scale.

Early commercial results, including the 74% sequential increase in Arbli^™ wholesale unit sales and initial REZENOPY^™ revenue contributions, reinforce our confidence in this strategy.

Looking Ahead: Continued Revenue Growth and Profitability in 2027

As we move through the remainder of 2026 and into 2027, our priorities remain centered on accelerating revenue growth, expanding commercial adoption, and improving operating performance.

For Arbli^™, we intend to build on recent institutional formulary wins, broaden physician engagement, and increase patient access across pediatric and cardiovascular treatment settings.

For REZENOPY^™, our focus is on expanding distribution, increasing institutional and treatment-center adoption, and building upon the initial commercial revenue generated following its launch.

We believe the combination of these initiatives positions Scienture to sustain sequential revenue growth as both products continue to scale. Our historically high gross margins and established commercial infrastructure provide the potential for meaningful operating leverage as sales increase, supporting our objective of achieving profitability in 2027.

Positioned for the Next Phase of Growth

Scienture today is a fundamentally different company than it was at the beginning of 2026. We have two FDA-approved products generating commercial revenue, expanding institutional adoption, established distribution and market access capabilities, and a high-margin business model designed to benefit from increasing sales volumes.

We believe the next phase of our growth will be defined by our ability to translate these commercial achievements into sustained revenue growth, improving financial performance, and ultimately profitability.

While meaningful work remains ahead, we are encouraged by the progress we have made and confident in the opportunities before us. Our focus remains on disciplined execution, responsible capital allocation, and building a sustainable specialty pharmaceutical company capable of delivering long-term shareholder value.

We thank our shareholders for their continued confidence and support and look forward to providing additional updates as we advance our commercial and financial objectives.

Sincerely,

Narasimhan Mani
President and Co-Chief Executive Officer

Shankar Hariharan
Executive Chairman and Co-Chief Executive Officer

About Arbli^™

Arbli^™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli^™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli^™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli^™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli^™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.

Arbli^™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli^™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.

INDICATION

Arbli^™ is an angiotensin II receptor blocker (ARB) indicated for:

• Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
• Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
• Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.

IMPORTANT SAFETY INFORMATION

• Do not take Arbli^™ when pregnant. When pregnancy is detected, discontinue Arbli^™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli^™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
• Do not co-administer Arbli^™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli^™ in patients with renal impairment (GFR <60 mL/min).
• Do not administer Arbli^™ in patients with severe hepatic impairment. Arbli^™ has not been studied in patients with severe hepatic impairment.
• The most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.

Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.

About Hypertension

Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or approximately 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.

About REZENOPY^™

REZENOPY^™ (naloxone hydrochloride) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present.

REZENOPY^™ nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device.

IMPORTANT SAFETY INFORMATION

REZENOPY^™ (naloxone hydrochloride) Nasal Spray 10 mg is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present and is not a substitute for emergency medical care.

Important Safety Information

• Contraindications: REZENOPY^™ nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.
• Warnings and Precautions:
  
  • Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer additional doses as necessary while awaiting emergency medical assistance.
  • Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
  • Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.
  • Risk of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular effects. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
• Adverse Reactions: The following adverse reactions were observed in a REZENOPY^™ nasal spray clinical study: upper abdominal pain, nasopharyngitis, and dysgeusia.

For complete product information, including Patient Information, please refer to the full Prescribing Information.

About Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, such as Arbli^™ and REZENOPY^™, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Stock Market LLC; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K, as amended, and subsequent reports filed with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

Contact:

SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Email: IR@Scienture.com

• Seasoned legal and compliance executive brings global product launch, strategic transaction and international operational experience as Candel prepares for its planned Biologics License Application (BLA) submission and potential commercialization

NEEDHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Maria Ostrovsky as General Counsel, effective November 3, 2026. Ms. Ostrovsky has 20 years of legal experience, most of it in the life sciences industry. She will oversee Candel’s legal and compliance functions, including corporate governance, and report to Candel’s President and Chief Executive Officer.

Ms. Ostrovsky joins Candel at a pivotal stage in the Company’s evolution, as it advances its clinical pipeline, prepares for a planned BLA submission for aglatimagene besadenovec (aglatimagene) in intermediate- to high-risk localized prostate cancer in the fourth quarter of 2026, and builds the capabilities needed to support potential commercialization, if approved.

“Maria brings a highly relevant combination of legal, compliance, global product launch and strategic transaction experience,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. “She has supported oncology launches in the United States and globally, built a healthcare compliance program at a commercial-stage biotech, and helped guide acquisition diligence, post-merger integration and international operations. As we prepare for our planned BLA submission and potential commercialization of aglatimagene, if approved, Maria will help us build scalable legal, governance and compliance capabilities for Candel’s next stage of growth. I am delighted to welcome her to our leadership team.”

“Candel is at an inflection point, with its first planned BLA submission ahead and a pipeline spanning several difficult-to-treat cancers,” said Maria Ostrovsky. “I am excited to join the leadership team and help establish the legal and compliance foundation needed to support Candel’s continued growth, potential transition toward commercialization and mission to bring new treatment options to patients.”

Ms. Ostrovsky most recently served as Senior Vice President, General Counsel and Chief Compliance Officer at Deciphera Pharmaceuticals (Deciphera), where she led the global legal and compliance function, built the company’s healthcare compliance program, contributed to two global product launches, supported acquisition diligence and post-merger integration, and oversaw a broad range of strategic and biotechnology transactions. She also built and led a U.S.- and EU-based legal and compliance team. She joined Deciphera in 2019. Before that, she held legal and compliance roles at TESARO, Inc. and at Takeda Pharmaceutical Company Limited (formerly Millennium Pharmaceuticals), where she supported oncology product launches in the United States and globally. Earlier in her career, she was a litigation associate at Cooley LLP and Cleary Gottlieb Steen & Hamilton LLP. Ms. Ostrovsky earned a J.D. from the University of Pennsylvania Law School and a B.A. from Middlebury College.

About aglatimagene besadenovec

Aglatimagene, Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s tumor. After intratumoral administration, HSV-tk enzyme activity results in conversion of prodrug (valacyclovir) into deoxyribonucleic acid (DNA)-incorporating nucleotide analogs, leading to immunogenic cell death in cells exhibiting DNA damage and proliferating cells, with subsequent release of a variety of tumor (neo)antigens in the tumor microenvironment. At the same time, the adenoviral serotype 5 capsid proteins promote inflammation through the induction of expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. Aglatimagene has the potential to treat a broad range of solid tumors. Encouraging monotherapy activity as well as combination activity with standard of care radiotherapy, surgery, chemotherapy, and immune checkpoint inhibitors have previously been shown in several nonclinical and clinical settings. More than 1,000 patients have been dosed with aglatimagene in clinical trials with a favorable tolerability profile to date, supporting the potential for use with standard of care, when indicated. Aglatimagene is currently not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any use.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (aglatimagene) is the lead product candidate from the adenovirus platform. The Company completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the FDA and published in The Lancet Oncology. The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.

Linoserpaturev is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult-to-treat, solid tumors; and expectations regarding the potential benefits conferred by regulatory designations. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; the timing of expected BLA submissions; that final data from the Company’s nonclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to commercialize any approved product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; the impact of the Company’s existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Investor Contact
Theodore Jenkins
Vice President, Investor Relations, and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) — StepStone Group Inc. (Nasdaq: STEP) today announced that the Company will release its results for the quarter ended September 30, 2026, after the market closes on Thursday, November 5, 2026. This represents results for the second quarter of the fiscal year ending March 31, 2027.

Webcast and Earnings Conference Call

Management will host a webcast and conference call on Thursday, November 5, 2026, at 5:00 pm ET to discuss the Company’s results for the second quarter of the fiscal year ending March 31, 2027. The webcast will be made available on the Shareholders section of the Company’s website at https://shareholders.stepstonegroup.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time to register. A replay will also be available on the shareholders website approximately two hours after the conclusion of the event.

To join as a live participant in the question and answer portion of the call, participants must register at https://register-conf.media-server.com/register/BI36eb874450a245fbb866f54cd2e0216c. Upon registering you will receive the dial-in number and a PIN to join the call as well as email confirmation with the details.

About StepStone

StepStone Group Inc. (Nasdaq: STEP) is a global private markets investment firm focused on providing customized investment solutions and advisory and data services to its clients. As of June 30, 2026, StepStone was responsible for approximately $913 billion of total capital, including $245 billion of assets under management. StepStone’s clients include some of the world’s largest public and private defined benefit and defined contribution pension funds, sovereign wealth funds and insurance companies, as well as prominent endowments, foundations, family offices and private wealth clients, which include high-net-worth and mass affluent individuals. StepStone partners with its clients to develop and build private markets portfolios designed to meet their specific objectives across the private equity, infrastructure, private debt and real estate asset classes.

Contacts

Shareholder Relations:
Seth Weiss
shareholders@stepstonegroup.com
1-212-351-6106

Media:
Jordan Niezelski / Maggie Duffy
Edelman
StepStone@edifi-dje.com

• Pauls Stradiņš Clinical University Hospital installs Genesis Robotic Magnetic Navigation System, establishing the first robotic program for the treatment of cardiac arrhythmia in Latvia
• First procedures successfully treated patients with a broad range of arrhythmia

ST. LOUIS, Oct. 22, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Pauls Stradiņš Clinical University Hospital in Riga, Latvia, has established the first robotic center for the treatment of cardiac arrhythmias in Latvia and has successfully treated initial patients with the Genesis Robotic Magnetic Navigation System.

“The introduction of the advanced Genesis technology at Pauls Stradiņš Clinical University Hospital reflects the hospital’s long-term commitment to developing highly specialized, modern, and patient safety focused healthcare services,” said Prof. Andrejs Ērglis, Head of the Latvian Cardiology Center at Stradiņš Hospital and Professor of Medicine at the University of Latvia. “We are proud to make this technology available to the benefit of arrhythmia patients, allowing all patients to benefit from the precision, controlled catheter movement, and safety of robotics. We particularly see value in our robotic program expanding the potential to treat complex cardiac arrhythmia.”

Pauls Stradiņš Clinical University Hospital is Latvia’s premier hospital, academic and research center, with a strong reputation in cardiology excellence. The Genesis Robotic Magnetic Navigation system introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmia may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.

“We are delighted to establish this new robotic electrophysiology center of excellence with Pauls Stradiņš Clinical University Hospital,” said David Fischel, Chairman and CEO of Stereotaxis. “We look forward to collaborating with the hospital and cardiology team to advance patient care in Latvia and advance clinical science that will have a global impact.”

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Cautionary Note Regarding Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, our overall liquidity and our ability to fund operations, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, our ability to manage and integrate recent acquisitions, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

Recognition reflects three years of sustained growth in revenue, profits, and shareholder returns

BOCA RATON, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading identity intelligence and analytics company, today announced that it has debuted at No. 43 on Fortune’s 2026 list of the 100 Fastest-Growing Companies. The ranking recognizes publicly traded companies that have delivered sustained growth in revenue, profits, and stock returns over a three-year period.

“We’re honored to be named to Fortune’s Fastest-Growing Companies list for the first time,” said Derek Dubner, red violet’s CEO. “This recognition reflects the combination that drives our business: differentiated, proprietary technology, a relentless focus on our customers, and a team that executes at a very high level. Delivering growth in revenue, profits, and shareholder returns is what we aim to do, and we believe we are still early in red violet’s evolution.”

Now in its 41st year, the annual ranking is based on a quantitative review of publicly traded companies. This is red violet’s first appearance on the list. It follows the company’s recognition in November 2025 as No. 107 of 500 companies on TIME’s inaugural America’s Growth Leaders ranking.

Ranking methodology

To qualify for the 2026 list, a company must trade on a major U.S. stock exchange, report in U.S. dollars, file quarterly reports with the SEC, and have traded continuously since June 30, 2023. It must have a minimum market capitalization of $225 million and a stock price of at least $5 on June 30, 2026, and latest-twelve-months revenue and net income, ended on or before April 30, 2026, of at least $50 million and $10 million, respectively. Companies must also have posted annualized growth in revenue and earnings per share of at least 15% over the three years ended on or before April 30, 2026. The full list and methodology are available at https://fortune.com/ranking/100-fastest-growing-companies/.

About red violet^®

At red violet, we build proprietary technologies and apply analytical capabilities to deliver identity intelligence. Our technology powers critical solutions, which empower organizations to operate with confidence. Our solutions enable the real-time identification and location of people, businesses, assets and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Our cloud-native, AI-embedded identity intelligence platform, CORE™, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. Our solutions are used today to enable frictionless commerce, enhance safety, and mitigate fraud and the related financial losses borne by society. For more information, please visit www.redviolet.com.

Forward-Looking Statements

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipate,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. Such forward-looking statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including whether the Company will continue to deliver growth in revenue, profits, and shareholder returns as it continues to evolve. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release and are advised to consider the factors listed above together with the additional factors under the heading “Forward-Looking Statements” and “Risk Factors” in red violet’s SEC Filings. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Company Contact:
Camilo Ramirez
Red Violet, Inc.
561-757-4500
ir@redviolet.com

CATSKILL, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) — Greene County Bancorp, Inc. (the “Company”) (NASDAQ: GCBC), the holding company for Bank of Greene (formerly the Bank of Greene County) and its subsidiary Greene County Commercial Bank, today reported net income for the three months ended September 30, 2026, which is the first quarter of the Company’s fiscal year ending June 30, 2027. Net income for the three months ended September 30, 2026 was $12.5 million, or $0.73 per basic and diluted share, as compared to $8.9 million, or $0.52 per basic and diluted share, for the three months ended September 30, 2025. Net income increased $3.6 million, or 40.9%, when comparing the three months ended September 30, 2026 and 2025.

Highlights:

• Net Income: $12.5 million for the three months ended September 30, 2026, a new record high
• Total Assets: $3.2 billion at September 30, 2026, a new record high
• Net Loans: $1.8 billion at September 30, 2026, a new record high
• Total Deposits: $2.8 billion at September 30, 2026, a new record high
• Return on Average Assets: 1.61% for the three months ended September 30, 2026
• Return on Average Equity: 17.73% for the three months ended September 30, 2026

“This quarter marked an important milestone as we introduced the Bank of Greene name and delivered record quarterly earnings,” said Donald Gibson, President & CEO. “Our new name reflects the broader region we serve and the relationships we continue to build across the Hudson Valley and Capital Region. Our commitment remains rooted in responsive personal service and local decision making. We are proud of our employees and remain focused on growing responsibly, supporting our customers, and delivering long-term shareholder value.”

Effective September 14, 2026, the Company’s primary banking subsidiary changed its legal name from the Bank of Greene County to Bank of Greene. The name change has no impact on the Bank’s operations and has no impact on the Company’s consolidated financial statements.

At the Company’s Annual Meeting on November 7, 2026, shareholders will consider a related proposal to amend the Company’s charter to change its legal name from Greene County Bancorp, Inc. to Greene Bancorp, Inc. If approved, the name change is expected to become effective following certification of the shareholder vote on November 9, 2026. The Company’s Nasdaq trading symbol “GCBC” and CUSIP number are not expected to change.

Total consolidated assets for the Company were $3.2 billion at September 30, 2026, primarily consisting of $1.8 billion of net loans and $1.2 billion of total securities available-for-sale and held-to-maturity. Consolidated deposits totaled $2.8 billion at September 30, 2026, consisting of retail, business, municipal and private banking relationships.

Pre-provision net income was $12.1 million for the three months ended September 30, 2026 as compared to $10.1 million for the three months ended September 30, 2025, an increase of $1.9 million, or 19.2%. Pre-provision net income measures the Company’s net income not including the provision for credit losses. Management believes that this non-GAAP measure assists investors in comprehending the impact of the provision for credit losses on the Company’s reported results, offering an alternative view of the Company’s performance and the Company’s ability to generate income in excess of its provision for credit losses.

The Company continues to manage its balance sheet with a focus on higher-yielding loans and securities, and disciplined deposit pricing. Deposit rates are actively managed in response to market interest rates and competitive conditions. These efforts contributed to a higher net interest margin for the three months ended September 30, 2026, compared with the same period in 2025.

Uncertainty surrounding inflation, the direction of interest rates, and geopolitical developments continues to influence the economic outlook. The Company remains focused on prudent risk management, maintaining financial strength and pursuing profitable growth, while delivering long-term shareholder value and serving the financial needs of its communities.

Selected highlights for the three months ended September 30, 2026, are as follows:

Net Interest Income and Margin

• Net interest income increased $4.4 million to $21.9 million for the three months ended September 30, 2026, from $17.5 million for the three months ended September 30, 2025. The increase in net interest income was primarily due to an increase in the average balance of interest-earning assets, which increased $159.3 million when comparing the three months ended September 30, 2026 and 2025, an increase in the average yield on interest-earning assets, which increased 16 basis points when comparing the three months ended September 30, 2026 and 2025, and a decrease in the average rate paid on interest-bearing liabilities, which decreased 30 basis points when comparing the three months ended September 30, 2026 and 2025. The increase in net interest income was offset by an increase in the average balance of interest-bearing liabilities, which increased $101.8 million when comparing the three months ended September 30, 2026 and 2025.

  Average loan balances increased $113.6 million and the yield on such loans increased 12 basis points when comparing the three months ended September 30, 2026 and 2025. The average balance of securities increased $58.4 million and the yield on such securities increased 24 basis points when comparing the three months ended September 30, 2026 and 2025. The average interest-bearing bank balances and federal funds decreased $14.6 million and the yield on interest-bearing bank balances and federal funds decreased 125 basis points when comparing the three months ended September 30, 2026 and 2025.

  The cost of NOW deposits decreased 39 basis points, the cost of certificates of deposits decreased 25 basis points, and the cost of savings and money market deposits decreased 4 basis points when comparing the three months ended September 30, 2026 and 2025. The growth in the average interest-bearing liabilities was primarily due to an increase in certificates of deposits of $51.8 million, an increase in average NOW deposits of $32.7 million, and an increase in average savings and money market deposits of $489,000 when comparing the three months ended September 30, 2026 and 2025. When comparing the three months ended September 30, 2026 and 2025, yields on interest-earning assets increased while the costs of interest-bearing deposits declined, reflecting continued asset repricing and the Company’s strategic reduction in deposit rates.

• Net interest rate spread increased 46 basis points to 2.71% for the three months ended September 30, 2026 as compared to 2.25% for the three months ended September 30, 2025.
  Net interest margin increased 45 basis points to 2.93% for the three months ended September 30, 2026 as compared to 2.48% for the three months ended September 30, 2025. The improvement reflected higher yields on loans and securities, combined with lower deposit costs, including reduced rates paid on NOW accounts and certificates of deposit. These benefits more than offset the decline in yields on interest-bearing bank balances and federal funds, supporting margin expansion alongside balance sheet growth.

• Net interest income on a taxable-equivalent basis includes the additional amount of interest income that would have been earned if the Company’s investment in tax-exempt securities and loans had been subject to federal and New York State income taxes yielding the same after-tax income. Tax-equivalent net interest margin increased 46 basis points to 3.24% for the three months ended September 30, 2026, from 2.78% for the three months ended September 30, 2025.

Credit Quality and Provision for Credit Losses

• Provision for credit losses amounted to a benefit of $432,000 for the three months ended September 30, 2026 as compared to a charge of $1.3 million for the three months ended September 30, 2025. The benefit for the three months ended September 30, 2026, was primarily attributable to the release of the allowance for credit losses associated with an individually evaluated loan that was repaid in full during the quarter, as well as improvements in the economic forecasts used in the Current Expected Credit Loss (“CECL”) model. The allowance for credit losses on loans to total loans receivable was 1.21% at September 30, 2026 as compared to 1.25% at June 30, 2026.
• Commercial and commercial real estate loans classified as substandard and special mention totaled $30.8 million at September 30, 2026, and $40.0 million at June 30, 2026, a decrease of $9.2 million. The decrease in the commercial and commercial real estate loans classified during the period ended September 30, 2026 was primarily due to upgrades of commercial real estate and commercial loans that were considered to be performing and paying in accordance with the terms of their loan agreements, and commercial real estate and commercial loans that were paid off during the period. Of the loans classified as substandard or special mention, $29.9 million were performing at September 30, 2026. There were no loans classified as doubtful or loss at September 30, 2026 or June 30, 2026.
• Net charge-offs on loans amounted to $48,000 and $60,000 for the three months ended September 30, 2026 and 2025, respectively, a decrease of $12,000. There were no material charge-offs in any loan segment during the three months ended September 30, 2026.
• Nonperforming loans amounted to $3.2 million at September 30, 2026 and $3.9 million at June 30, 2026. The activity in nonperforming loans during the period included $1.2 million in loan repayments, $163,000 in loans returning to performing status, $91,000 in charge-offs or transfers to foreclosure, and $720,000 of loans placed into nonperforming status. At September 30, 2026, nonperforming assets were 0.10% of total assets as compared to 0.12% at June 30, 2026. At September 30, 2026, nonperforming loans were 0.18% of net loans as compared to 0.23% at June 30, 2026.

Noninterest Income and Noninterest Expense

• Noninterest income decreased $1.1 million, or 27.0%, to $2.9 million for the three months ended September 30, 2026 as compared to $4.0 million for the three months ended September 30, 2025. The decrease during the three months ended September 30, 2026 was primarily due to a $1.2 million loss on sales of securities available-for-sale and a decrease of $289,000 in income earned on customer interest rate swaps. This was partially offset by a $140,000 increase in investment services income.

• Noninterest expense increased $740,000, or 7.4%, to $10.8 million for the three months ended September 30, 2026 as compared to $10.1 million for the three months ended September 30, 2025. The increase during the three months ended September 30, 2026 was primarily due to an increase of $582,000 in salaries and employee benefits and an increase of $367,000 in the allowance for credit losses unfunded commitment expense, due to an increase in the Company’s contractual obligation to extend credit.

Income Taxes

• Provision for income taxes reflects the expected tax associated with the pre-tax income generated for the given period and certain regulatory requirements. The effective tax rate was 13.4% for the three months ended September 30, 2026 and 12.9% for the three months ended September 30, 2025. The statutory tax rate is impacted by the benefits derived from tax-exempt bond and loan income, the Company’s real estate investment trust subsidiary income, income received on the bank owned life insurance and tax credits to arrive at the effective tax rate. The increase during the three months ended September 30, 2026 was primarily due to higher mix of pre-tax income and reflects a lower mix of tax-exempt income from municipal bonds, tax advantage loans, and bank owned life insurance in proportion to pre-tax income.

Balance Sheet Summary

• Total assets of the Company were $3.2 billion at September 30, 2026 and June 30, 2026.
• Total cash and cash equivalents for the Company were $135.0 million at September 30, 2026 and $144.9 million at June 30, 2026. The Company has continued to maintain strong capital and liquidity positions as of September 30, 2026.
• Securities available-for-sale and held-to-maturity increased $48.6 million, or 4.1%, to $1.23 billion at September 30, 2026 as compared to $1.18 billion at June 30, 2026. Securities purchased totaled $148.1 million during the three months ended September 30, 2026, primarily consisting of $125.2 million of state and political subdivision securities, $13.9 million of mortgage-backed securities, and $9.0 million of collateralized mortgage obligations. Principal pay-downs and maturities during the three months ended September 30, 2026, amounted to $87.0 million, primarily consisting of $66.8 million of state and political subdivision securities, $13.0 million of mortgage-backed securities, $3.0 million in U.S. Treasuries, $3.0 million in corporate debt securities, and $1.2 million of collateralized mortgage obligations.
• Net loans receivable increased $23.1 million, or 1.3%, to $1.8 billion at September 30, 2026 as compared to $1.7 billion at June 30, 2026. Loan growth experienced during the three months ended September 30, 2026, consisted primarily of $18.3 million in commercial real estate loans, $3.7 million in commercial loans, and $2.5 million in home equity loans. The allowance for credit losses on loans decreased $417,000, or 1.9%, to $21.4 million at September 30, 2026 as compared to $21.9 million at June 30, 2026. The decrease in the allowance for credit losses was primarily attributable to the release of the allowance for credit losses associated with an individually evaluated loan that was repaid in full during the quarter, as well as improvements in the economic forecasts used in the CECL model.
• Deposits totaled $2.8 billion at September 30, 2026 as compared to $2.7 billion at June 30, 2026, an increase of $134.4 million, or 5.0%. The Company had $41.6 million and $52.4 million of brokered deposits at September 30, 2026 and June 30, 2026, respectively. NOW deposits increased $111.3 million, or 5.6%, certificates of deposits increased $19.1 million, or 7.7%, and noninterest bearing deposits increased $13.9 million, or 9.9%, when comparing September 30, 2026 and June 30, 2026. Savings deposits decreased $5.5 million, or 2.3%, and money market deposits decreased $4.4 million, or 4.4%, when comparing September 30, 2026 and June 30, 2026.

• Borrowings amounted to $66.2 million at September 30, 2026 as compared to $155.1 million at June 30, 2026, a decrease of $88.9 million. At September 30, 2026, borrowings included $40.0 million of overnight borrowings with the Federal Home Loan Bank of New York (“FHLB”), $20.0 million of Fixed-to-Floating Rate Subordinated Notes and $6.2 million of long-term borrowings with the FHLB.

  As previously announced, on September 15, 2026, the Company redeemed $10.0 million in aggregate principal amount of the $30.0 million 3.00% Fixed-to-Floating Rate Subordinated Notes, due September 15, 2031. Following the redemption, $20.0 million in aggregate principal amount of the Notes remains outstanding. The redemption was funded by cash on hand.

• Shareholders’ equity increased to $286.0 million at September 30, 2026 as compared to $277.8 million at June 30, 2026, resulting primarily from net income of $12.5 million, partially offset by an increase in accumulated other comprehensive loss of $3.5 million and dividends declared and paid of $859,000. Under the Company’s current stock repurchase program, there were no repurchases during the three months ended September 30, 2026. As of the three months ended September 30, 2026, 398,657 shares remain in the stock repurchase program.

Corporate Overview

Greene County Bancorp, Inc. is the holding company for Bank of Greene, and its subsidiary Greene County Commercial Bank. The Company is the leading provider of community-based banking services throughout the Hudson Valley and Capital Region of New York State. Its customers include individuals, businesses, municipalities and other institutions. Greene County Bancorp, Inc. (GCBC) is publicly traded on the Nasdaq Capital Market and is dedicated to promoting economic development and a high quality of life in the communities it serves. For more information on Greene County Bancorp, Inc., visit www.bankofgreene.com.

Forward-Looking Statements

In addition to historical information, this earnings release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which describes the future plans, strategies and expectations of the Company. Forward-looking statements can be identified by the use of words such as “estimate,” “project,” “believe,” “intend,” “anticipate,” “assume,” “plan,” “seek,” “expect,” “will,” “may,” “should,” “indicate,” “would,” “contemplate,” “continue,” “target” and words of similar meaning. Forward-looking statements are based on our current beliefs and expectations and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control. In addition, these forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Accordingly, you should not place undue reliance on such statements. We are under no duty to and do not take any obligation to update any forward-looking statements after the date of this report. Factors which could have a material adverse effect on the operations of the Company and its subsidiaries include, but are not limited to, changes in general economic conditions, interest rates and inflation; changes in asset quality; our ability to access cost-effective funding; fluctuations in real estate values; changes in laws or regulations; the effects of any federal government shutdown; changes in liquidity, including the size and composition of our deposit portfolio and the percentage of uninsured deposits in the portfolio; changes in technology; failures or breaches of our IT security systems; our ability to introduce new products and services and capitalize on growth opportunities; changes in accounting policies and practices; our ability to retain key employees; and the effects of natural disasters and geopolitical events, including terrorism, conflict and acts of war.

For more information, please see our reports filed with the United States Securities and Exchange Commission (“SEC”), including our most recent annual report on Form 10-K and quarterly reports on Form 10-Q.

Non-GAAP Measures

In addition to presenting information in conformity with accounting principles generally accepted in the United States of America (GAAP), this news release contains financial information determined by methods other than GAAP (non-GAAP). The following measures used in this release, which are commonly utilized by financial institutions, have not been specifically exempted by the Securities and Exchange Commission (“SEC”) and may constitute “non-GAAP financial measures” within the meaning of the SEC’s rules.

The Company has provided in this news release supplemental disclosures for the calculation of net interest margin utilizing a fully taxable-equivalent adjustment and pre-provision net income. Management believes that the non-GAAP financial measures disclosed by the Company from time to time are useful in evaluating the Company’s performance and that such information should be considered as supplemental in nature and not as a substitute for or superior to the related financial information prepared in accordance with GAAP. Our non-GAAP financial measures may differ from similar measures presented by other companies. Refer to the tables on page 9 for Non-GAAP to GAAP reconciliations.

Greene County Bancorp, Inc.
Consolidated Statements of Income and Selected Financial Ratios (Unaudited)

	At or for the Three Months
	Ended September 30,
Dollars in thousands, except share and per share data		2026			2025
Interest income	$34,598			$31,623
Interest expense		12,709			14,103
Net interest income		21,889			17,520
(Benefit) Provision for credit losses		(432	)		1,257
Noninterest income		2,909			3,986
Noninterest expense		10,801			10,061
Income before taxes		14,429			10,188
Tax provision		1,927			1,318
Net income	$12,502			$8,870
Basic and diluted EPS	$0.73			$0.52
Weighted average shares outstanding		17,025,485			17,026,828
Dividends declared per share (4)	$0.11			$0.10
Selected Financial Ratios
Return on average assets(1)		1.61%			1.21%
Return on average equity(1)		17.73%			14.59%
Net interest rate spread(1)		2.71%			2.25%
Net interest margin(1)		2.93%			2.48%
Fully taxable-equivalent net interest margin(2)		3.24%			2.78%
Efficiency ratio(3)		43.56%			46.78%
Non-performing assets to total assets		0.10%			0.12%
Non-performing loans to net loans		0.18%			0.22%
Allowance for credit losses on loans to non-performing loans		664.87%			597.92%
Allowance for credit losses on loans to total loans		1.21%			1.27%
Shareholders’ equity to total assets		8.82%			8.11%
Dividend payout ratio(4)		15.07%			19.23%
Actual dividends paid to net income(5)		6.87%			8.80%
Book value per share	$16.80			$14.58
(1) Ratios are annualized when necessary.
(2) Interest income calculated on a taxable-equivalent basis (non-GAAP) includes the additional interest income that would have been earned if the Company’s investment in tax-exempt securities and loans had been subject to federal and New York State income taxes yielding the same after-tax income.
(3) The efficiency ratio has been calculated as noninterest expense divided by the sum of net interest income and noninterest income.
(4) The dividend payout ratio has been calculated based on the dividends declared per share divided by basic earnings per share. No adjustments have been made to account for dividends waived by Greene County Bancorp, MHC (“MHC”), the Company’s majority shareholder, owning 54.1% of the shares outstanding.
(5) Dividends declared divided by net income. The MHC waived its right to receive dividends declared during the three months ended June 30, 2025, September 30, 2025, December 31, 2025, June 30, 2026, and September 30, 2026. Dividends declared during the three months ended March 31, 2026, were paid to the MHC.

Greene County Bancorp, Inc.
Consolidated Statements of Financial Condition (Unaudited)

	At September 30, 2026				At June 30, 2026
Dollars in thousands, except share data
Assets
Cash and due from banks	$24,519				$12,306
Interest-bearing deposits		110,480				132,599
Total cash and cash equivalents		134,999				144,905
Long-term certificate of deposit		1,225				1,225
Securities available-for-sale, at fair value		393,042				373,810
Securities held-to-maturity, at amortized cost, net of
allowance for credit losses of $467 and $530		832,982				803,553
Equity securities, at fair value		402				388
Federal Home Loan Bank stock, at cost		4,322				7,777
Loans receivable		1,776,011				1,753,342
Allowance for credit losses on loans		(21,442)				(21,859)
Net loans receivable		1,754,569				1,731,483
Premises and equipment, net		14,663				14,839
Bank owned life insurance		69,631				68,895
Foreclosed real estate		135				–
Accrued interest receivable		18,609				17,184
Prepaid expenses and other assets		18,041				19,368
Total assets	$3,242,620				$3,183,427
Liabilities and shareholders’ equity
Noninterest bearing deposits	$154,167				$140,229
Interest bearing deposits		2,693,675				2,573,170
Total deposits		2,847,842				2,713,399
Borrowings, short-term		40,000				119,000
Borrowings, long-term		6,166				6,166
Subordinated notes payable, net		20,000				29,979
Accrued expenses and other liabilities		42,629				37,052
Total liabilities		2,956,637				2,905,596
Total shareholders’ equity		285,983				277,831
Total liabilities and shareholders’ equity	$3,242,620				$3,183,427
Common shares outstanding		17,025,485				17,025,485
Treasury shares		197,195				197,195

The above information is preliminary and based on the Company’s data available at the time of presentation.

Non-GAAP to GAAP Reconciliations

The following table summarizes the adjustments made to arrive at the fully taxable-equivalent net interest margins.

		For the three months ended September 30,
(Dollars in thousands)			2026			2025
Net interest income (GAAP)		$21,889			$17,520
Tax-equivalent adjustment(1)			2,286			2,110
Net interest income-fully taxable-equivalent basis (non-GAAP)		$24,175			$19,630
Average interest-earning assets (GAAP)		$2,988,625			$2,829,350
Net interest margin-fully taxable-equivalent basis (non-GAAP)			3.24%			2.78%
(1) Interest income calculated on a taxable-equivalent basis (non-GAAP) includes the additional interest income that would have been earned if the Company’s investment in tax-exempt securities and loans had been subject to federal and New York State income taxes yielding the same after-tax income. The rate used for this adjustment was 21% for federal income taxes for the three months ended September 30, 2026 and 2025, 4.44% for New York State income taxes for the three months ended September 30, 2026 and 2025.

The following table summarizes the adjustments made to arrive at pre-provision net income.

	For the three months ended September 30,
(Dollars in thousands)		2026			2025
Net income (GAAP)	$12,502			$8,870
(Benefit) Provision for credit losses		(432)			1,257
Pre-provision net income (non-GAAP)	$12,070			$10,127

The above information is preliminary and based on the Company’s data available at the time of presentation.

For Further Information Contact:
Donald E. Gibson
President & CEO
(518) 943-2600
donaldg@bankofgreene.com

Nick Barzee
SVP & CFO
(518) 943-2600
nickb@bankofgreene.com

• Intravenous SCY-247 was generally well tolerated in healthy participants, with no drug-related serious adverse events
• Once-daily intravenous doses of 50 mg or higher achieved exposures at or above the target identified in murine models of invasive candidiasis
• Company expects to initiate Phase 2 development of SCY-247 in oral and IV formulations in 2027, subject to regulatory agreement
• SCY-247 development is advancing with the support of a BARDA contract providing up to approximately $214 million in non-dilutive funding if milestones are achieved

JERSEY CITY, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”, or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced topline results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of the intravenous (IV) formulation of SCY-247, its second-generation triterpenoid (fungerp) antifungal candidate. SCY-247 is under development in both oral and intravenous (IV) formulations for the treatment and prevention of invasive fungal infections with the potential to provide therapeutic advantages by having activity against drug-resistant fungi.

“With Phase 1 studies of both the intravenous and oral formulations of SCY-247 now complete, we can refine our plans for the next stage of development of this second-generation fungerp, designed to address the growing threat of antimicrobial resistance,” said Todd Minga, M.D., SVP of Research and Development at Scynexis. “Having both intravenous and oral formulations could provide flexibility in managing patients with invasive candidiasis and those at risk of invasive fungal diseases. We look forward to initiating a Phase 2 study next year, subject to agreement with the FDA.”

Recently, Scynexis was awarded a BARDA contract (75A50126C00007) providing up to approximately $214 million in non-dilutive funding, if milestones are achieved, to advance the development of SCY-247. The award is structured as a cost-share arrangement, with BARDA providing support for eligible SCY-247 costs. The Company expects to fund its share of near-term program costs for SCY-247 within its existing operating plan. The Company’s previously communicated development plans for SCY-770 to initiate a Phase 2 study in the fourth quarter of 2026 and the Company’s projected cash runway into 2029 remain unchanged.

Phase 1 Study Results

The study evaluated the safety and characterized the pharmacokinetics of intravenous SCY-247 to inform progression to, and dose selection for, a Phase 2 study in patients with invasive candidiasis. The Phase 1 study enrolled 56 healthy participants across seven cohorts: 42 received SCY-247 by peripheral intravenous infusion and 14 received placebo. The study evaluated single ascending doses up to 300 mg and multiple ascending doses administered once daily for seven days up to 200 mg.

SCY-247 administered by peripheral intravenous infusion was generally well tolerated. The most commonly reported adverse reactions were mild to moderate erythema and pain at the infusion site. There were no drug-related serious adverse events or discontinuations due to a related adverse event.

Intravenous doses of 50 mg once daily or higher achieved exposures at or above the efficacy target identified in murine models of invasive candidiasis (AUC_0–24 of 20 µg·h/mL). A previously completed Phase 1 study indicated that oral doses of 100 mg or higher are also anticipated to achieve the target exposure for efficacy. Overall, the safety, tolerability, and pharmacokinetic profile observed in this study support the continued clinical development of SCY-247. Further details of the results from this study will be presented at an upcoming scientific meeting.

Invasive candidiasis is associated with high mortality, and resistance to the limited available antifungal options is making treatment increasingly challenging. Designed to address these limitations, SCY-247 has demonstrated in vitro and in vivo activity against several challenging Candida strains, including Candida auris, as well as most azole- and echinocandin-resistant strains. SCY-247 has been granted Orphan Drug, Qualified Infectious Disease Product (QIDP) and Fast Track designations by the U.S. Food and Drug Administration.

Future activities for this project may be funded in whole or in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Center for the Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50126C00007.

About SCY-247

SCY-247 is a second-generation triterpenoid (fungerp) antifungal candidate being developed for the treatment of invasive candidiasis and the prevention of invasive fungal diseases. As a member of a novel structural class, SCY-247 has a differentiated mechanism of action from existing antifungal classes and has demonstrated in vitro activity against a broad range of fungal pathogens, including strains resistant to currently available therapies. SCY-247 has been granted Orphan Drug, Qualified Infectious Disease Product (QIDP) and Fast Track designations by the U.S. Food and Drug Administration. Recently, Scynexis was awarded a BARDA contract (75A50126C00007) providing up to approximately $214 million in non-dilutive funding to advance the development of SCY-247.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development for the treatment and prevention of invasive fungal diseases. For more information, visit www.scynexis.com.

Forward-Looking Statements

Statements contained in this press release regarding expected future events or results are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: the Company’s expectation to initiate Phase 2 development of SCY-247 in oral and IV formulations in 2027, subject to regulatory agreement; the potential for SCY-247 to provide therapeutic advantages of both an oral and IV formulation; the amount and timing of any BARDA funding (under contract 75A50126C00007);   the Company’s expectation to fund its share of near-term program costs for SCY-247 within its existing operating plan; the anticipated initiation of the SCY-770 Phase 2 study in Q4 of 2026; the statements concerning the Company’s cash runway into 2029, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products, including the risk that SCYNEXIS may not reach alignment with the FDA on the planned Phase 2 study designs on the anticipated timelines or at all, and the risk that BARDA does not exercise one or more options under the BARDA contract (75A50126C00007). For the Company, this includes the future prospects of the Company’s SCY-247 and SCY-770 programs, the timing and results of the Company’s anticipated Phase 2 clinical studies, stock price volatility and uncertainties relating to the financial markets, the medical community and the global economy, and the impact of instability in general business and economic conditions, including changes in inflation and interest rates. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation, its most recent Annual Report on Form 10-K filed on March 4, 2026, including under the caption “Risk Factors,” and in other filings the Company makes with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: 
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
jfraunces@lifesciadvisors.com

Approximately 22-day field program to be managed by Lonquist, with results to feed 3D gravity inversion and 2D modelling along key seismic profiles

VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has secured the approvals, permits and land access permissions required to commence its planned ground gravity survey at the Robinsons River Salt Project in Newfoundland and Labrador. The current survey design comprises approximately 500 planned measurement stations, with field acquisition expected to be undertaken by McKeown Exploration Services under the management of Lonquist Field Service (Canada), ULC (“Lonquist”). The survey will target gaps in existing gravity coverage and areas of exploration interest across the Project, including areas west of the Cloverleaf target and within the eastern block. Planned stations include traverses along selected historical seismic lines, allowing the new gravity measurements to be evaluated alongside existing seismic interpretations. Field acquisition is estimated to require approximately 22 working days, with final station locations and timing subject to access, weather and ground conditions, and completion of contractor arrangements.

The Mineral Lands Division of Newfoundland and Labrador’s Department of Energy and Mines approved the proposed geophysical survey program through Letter of Acceptance E260510, dated October 16, 2026. The survey will be conducted in accordance with the letter’s conditions, including in regard to environmental protection and archaeological requirements.

The Company aims to compare the new measurements with the Project’s historical airborne gravity-gradiometry data to assess consistency between the datasets, with the goal of improving confidence in the subsurface interpretation. The Company is planning to subsequently complete a modelling program that would include three-dimensional gravity inversion and targeted two-dimensional modelling along key seismic profiles near potential drilling locations. This work is intended to refine the interpretation of prospective salt structures and support decisions on future exploration drilling.

“We now have a detailed survey plan that builds directly on the technical work completed at Robinsons River,” said Paul Sparkes, Chief Executive Officer of Vortex. “These additional measurements will help us better understand the priority target areas and make more informed decisions about where to focus the next phase of exploration.”

The program advances the ground gravity survey announced on September 3, 2026, and Lonquist’s engagement announced on September 14, 2026. Vortex will provide further updates as fieldwork progresses. Gravity interpretations are non-unique and require integration with geological and drilling information; gravity data alone cannot establish salt composition, thickness or continuity.

Figure 1. Planned ground gravity station locations relative to the Robinsons River project licences and historical seismic lines. Station locations remain subject to field conditions and access.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Jared Suchan, Ph.D., P.Geo., Vice President of Exploration of the Company and a “Qualified Person” as defined by National Instrument 43-101.

For additional information concerning the Project and the Company’s data-verification and quality-assurance procedures, readers are referred to the Company’s technical report entitled Independent Technical Report on the Robinsons River Salt Property, dated July 31, 2023, available under the Company’s profile on SEDAR+.

About Vortex Energy Corp.

Vortex Energy Corp. is an exploration stage company engaged principally in the acquisition, exploration, and development of mineral properties in North America. The Company is currently advancing its Robinson River Salt Project comprised of a total of 942 claims covering 23,500 hectares located approximately 35 kilometres south of the town of Stephenville in the Province of Newfoundland & Labrador. The Robinson River Salt Project is prospective for both salt and hydrogen salt cavern storage. The Company is also currently advancing its Fire Eye Uranium Property in the Athabasca Basin, a region renowned for its uranium deposits.

On Behalf of the Board of Directors

Paul Sparkes

Chief Executive Officer, Director

+1 (778) 819-0164

info@vortexenergycorp.com

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information relates to future events or future performance and reflects management’s current expectations or beliefs regarding future events. Forward-looking information is often identified by words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, “should”, “will” and similar expressions, or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. In particular, this press release contains forward-looking information regarding, among other things: the commencement, conduct, scope, timing and completion of the planned ground gravity survey at the Robinsons River Salt Project (the “Project”); the number and final locations of measurement stations; the engagement, availability and performance of Lonquist Field Service (Canada), ULC and McKeown Exploration Services; the Company’s ability to satisfy the conditions of applicable approvals and permits and obtain and maintain required land access; the anticipated duration of field acquisition; the collection, processing, interpretation and integration of new gravity measurements with historical airborne gravity-gradiometry, seismic, geological and drilling information; the completion of three-dimensional gravity inversion and targeted two-dimensional modelling; the ability of the survey and modelling to improve confidence in subsurface interpretations, refine prospective salt structures and support the selection of potential drilling locations and decisions regarding future exploration drilling; and the provision of further updates as fieldwork progresses. 

Forward-looking information is based on assumptions that management considers reasonable as of the date of this press release, including, without limitation, assumptions that: the Company will have sufficient financial, technical and personnel resources to carry out the planned program; contractor arrangements will be completed and the contractors will be available and perform as anticipated; all required approvals, permits and land access permissions will remain in good standing and their conditions will be satisfied; field access, weather and ground conditions will permit the survey to proceed substantially as planned; the planned stations can be surveyed and reliable data can be collected, processed and interpreted; historical datasets are sufficiently accurate, complete and compatible for the contemplated comparisons and modelling; the survey and modelling will generate information useful for refining the Company’s geological interpretation and future exploration planning; and there will be no material adverse change in applicable laws, regulatory requirements, commodity or capital-market conditions, or the Company’s business and financing plans. 

Although management believes that the assumptions and expectations reflected in such forward-looking information are reasonable, there can be no assurance that they will prove to be correct. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such information. These risks and uncertainties include, without limitation: the survey may be delayed, modified, suspended or not completed due to contractor availability or performance, access restrictions, weather, ground conditions, equipment failure, safety or logistical issues, cost escalation, financing constraints, regulatory requirements or other circumstances; approvals, permits or land access permissions may be amended, suspended, revoked or subject to additional conditions; final station locations, survey coverage and timing may differ from those currently contemplated; collected data may be incomplete, inconsistent, of insufficient quality or incapable of being integrated with historical datasets; gravity interpretations are non-unique and may not accurately identify the geometry, composition, thickness, continuity or economic significance of subsurface features; the contemplated inversion and modelling may not be completed, may produce inconclusive or unexpected results, or may not identify suitable drilling targets; historical exploration information may be inaccurate, incomplete or not independently verifiable; exploration results may not support further work, drilling or development; future exploration programs may not be approved, financed or completed; costs may exceed estimates; and risks inherent in mineral exploration and development, including geological uncertainty, environmental and archaeological requirements, community and stakeholder considerations, changes in laws or regulatory requirements, and the availability of capital, personnel, equipment and services. Additional risks are described in the Company’s continuous disclosure filings available under its profile on SEDAR+. Readers are cautioned that the foregoing list is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Readers should not place undue reliance on forward-looking information. The forward-looking information contained in this press release is expressly qualified by this cautionary statement. 

The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of this press release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b3a03ba2-9c45-437c-ba72-32cb85aeff53

STOUGHTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it will report third quarter 2026 financial results before the market opens on Thursday November 5, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.

Conference Call Information 
To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q3 2026 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical is a dynamic biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system (CNS) and pain conditions.  Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.    

With a portfolio of differentiated ADHD medications, anchored by JORNAY PM^® (methylphenidate HCl) CII and AZSTARYS^® (serdexmethylphenidate and dexmethylphenidate) CII, and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives.  

For more information, please visit collegiumpharma.com or find us on LinkedIn.   

Investor Contacts:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com

Media Contact:
Jessica Cotrone
Senior Vice President, Communications & Corporate Affairs
communications@collegiumpharma.com

WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET to discuss its financial results and provide corporate update for the fiscal second quarter ended September 30, 2026.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer section should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

About Replimune

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com

Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com